ISSAR Pharmaceuticals displays an outstanding expertise in providing new formulations with an objective to introduce first-to-market products providing dosage forms with better patient compatibility and convenience. From laboratory procedures to GMP, ISSAR takes continuous initiatives towards technology adaptation and innovation.

Pharmaceutical formulation development is based on compilation of activities which help in determining the dosage form, route, composition and manufacturing. These involve functions such as pre-formulation, including analytical assay development and characterization, excipient screening to stabilize or enhance the solubility of the product and dosage form development, whether it involves a solid, topical, aerosol, liquid or lyophilized dosage form. Formulation development may also include assessing delivery options and delivery device compatibility.

ISSAR’S formulation development strategy is based on in-depth study of patents, scientific literature, compendia information, Critical Quality Attributes (CQA) and Quality Target Product Profiles (QTPP) of the respective drug delivery system and nature of the molecule.

ISSAR has an FDA-compliant 62,000 sq ft manufacturing facility for topical, injectable, and other peptide formulations at varying scales from gram to multi kilogram scale. The synthesis of novel therapeutic peptides is carried out by Solid phase peptide synthesis process. The raw materials of the molecules are processed through synthesis and Cleavage, followed by purification. The purified product is lyophilized to obtain the peptide in its final powder form. The peptide obtained is then formulated for manufacturing the specific ointment, cream or lotion.